Ad is loading...
MLYS
Price
$11.48
Change
-$0.69 (-5.67%)
Updated
Nov 15 closing price
NMRA
Price
$10.84
Change
-$0.85 (-7.27%)
Updated
Nov 15 closing price
Ad is loading...

MLYS vs NMRA

Header iconMLYS vs NMRA Comparison
Open Charts MLYS vs NMRABanner chart's image
Mineralys Therapeutics
Price$11.48
Change-$0.69 (-5.67%)
Volume$224.9K
CapitalizationN/A
Neumora Therapeutics
Price$10.84
Change-$0.85 (-7.27%)
Volume$956.65K
CapitalizationN/A
MLYS vs NMRA Comparison Chart
Loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NMRA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
MLYS vs. NMRA commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLYS is a Sell and NMRA is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (MLYS: $11.48 vs. NMRA: $10.84)
Brand notoriety: MLYS and NMRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLYS: 128% vs. NMRA: 78%
Market capitalization -- MLYS: $570.86M vs. NMRA: $1.75B
MLYS [@Biotechnology] is valued at $570.86M. NMRA’s [@Biotechnology] market capitalization is $1.75B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLYS’s FA Score shows that 0 FA rating(s) are green whileNMRA’s FA Score has 0 green FA rating(s).

  • MLYS’s FA Score: 0 green, 5 red.
  • NMRA’s FA Score: 0 green, 5 red.
According to our system of comparison, MLYS is a better buy in the long-term than NMRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLYS’s TA Score shows that 5 TA indicator(s) are bullish while NMRA’s TA Score has 4 bullish TA indicator(s).

  • MLYS’s TA Score: 5 bullish, 5 bearish.
  • NMRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MLYS is a better buy in the short-term than NMRA.

Price Growth

MLYS (@Biotechnology) experienced а -18.23% price change this week, while NMRA (@Biotechnology) price change was -19.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

MLYS is expected to report earnings on Nov 11, 2024.

NMRA is expected to report earnings on Nov 12, 2024.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NMRA($1.75B) has a higher market cap than MLYS($571M). MLYS YTD gains are higher at: 33.488 vs. NMRA (-36.422). MLYS has higher annual earnings (EBITDA): -134.51M vs. NMRA (-294.11M). NMRA has more cash in the bank: 372M vs. MLYS (311M). MLYS (0) and NMRA (0) have equivalent revenues.
MLYSNMRAMLYS / NMRA
Capitalization571M1.75B33%
EBITDA-134.51M-294.11M46%
Gain YTD33.488-36.422-92%
P/E RatioN/AN/A-
Revenue00-
Total Cash311M372M84%
Total DebtN/A3.61M-
TECHNICAL ANALYSIS
Technical Analysis
MLYSNMRA
RSI
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
75%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
75%
Bullish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 3 days ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
76%
Advances
ODDS (%)
Bullish Trend 12 days ago
89%
Bullish Trend 7 days ago
90%
Declines
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 5 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
67%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
88%
View a ticker or compare two or three
Ad is loading...
MLYS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
NMRA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FPPSX11.77-0.01
-0.08%
MFS Prudent Investor R2
SVAAX6.22-0.02
-0.32%
Federated Hermes Strategic Value Div A
RDWEX10.64-0.08
-0.75%
American Funds Dvlpg Wld Gr&Inc R4
TVRCX17.31-0.19
-1.09%
NAA Allocation Fund C
ALBCX75.08-0.93
-1.22%
Alger Growth & Income C

MLYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLYS has been loosely correlated with RCKT. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MLYS jumps, then RCKT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLYS
1D Price
Change %
MLYS100%
-5.67%
RCKT - MLYS
42%
Loosely correlated
-5.67%
PRME - MLYS
42%
Loosely correlated
-6.95%
ADCT - MLYS
41%
Loosely correlated
-9.81%
QSI - MLYS
40%
Loosely correlated
-5.77%
RCUS - MLYS
40%
Loosely correlated
-0.44%
More

NMRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NMRA has been loosely correlated with SNDX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if NMRA jumps, then SNDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NMRA
1D Price
Change %
NMRA100%
-7.27%
SNDX - NMRA
39%
Loosely correlated
-5.72%
ABOS - NMRA
37%
Loosely correlated
-8.05%
ADCT - NMRA
36%
Loosely correlated
-9.81%
MLYS - NMRA
36%
Loosely correlated
-5.67%
AURA - NMRA
34%
Loosely correlated
-5.02%
More